Clínica e Investigación en Arteriosclerosis (English Edition)最新文献

{"title":"Functional foods and nutraceuticals in the treatment of hypercholesterolemia: Statement of the Spanish Society of Arteriosclerosis 2023","authors":"Pablo Pérez-Martínez ,&nbsp;Emilio Ros ,&nbsp;Juan Pedro-Botet ,&nbsp;Fernando Civeira ,&nbsp;Vicente Pascual ,&nbsp;Carmen Garcés ,&nbsp;Rosa Solá ,&nbsp;Francisco Pérez-Jiménez ,&nbsp;José M. Mostaza","doi":"10.1016/j.artere.2023.09.003","DOIUrl":"https://doi.org/10.1016/j.artere.2023.09.003","url":null,"abstract":"<div><p>Given the progressive increase in the number of these products and their rising use by the population, the Spanish Society of Arteriosclerosis (SEA) has considered it appropriate to review the available information, select the results of the scientifically more robust studies and take a position on their usefulness, to recommend to health professionals and the general population their potential utility in terms of efficacy and their possible benefits and limitations. The following clinical scenarios have been identified in which these products could be used and will be analyzed in more detail in this document: (1) Hypolipidemic treatment in subjects with statin intolerance. (2) Hypolipidemic treatment \"a la carte\" in individuals in primary prevention. (3) Long-term cardiovascular prevention in individuals with no indication for lipid-lowering therapy. (4) Patients with optimized lipid-lowering treatment who do not achieve therapeutic objectives.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 5","pages":"Pages 248-261"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49760781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remnant cholesterol, vascular risk, and prevention of atherosclerosis","authors":"Xavier Pintó ,&nbsp;Marta Fanlo ,&nbsp;Virginia Esteve ,&nbsp;Jesús Millán ,&nbsp;on behalf of the Atherogenic Dyslipidemia Working Group, Spanish Society of Arteriosclerosis (SEA)","doi":"10.1016/j.artere.2023.07.005","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.005","url":null,"abstract":"<div><p><span>In patients<span> who have achieved optimal LDL-C control, there remains a residual risk of atherothrombotic cardiovascular disease (ACVD) related to alterations in lipid metabolism, where alterations in triglyceride-rich lipoproteins (TGRLP) and the cholesterol they contain, called </span></span><em>remnant cholesterol</em><span><span>, play a major role. Remnant cholesterol has an association with residual risk of CVD that is independent of LDL-C and has been demonstrated in epidemiological and Mendelian randomisation studies, and in analyses of </span>clinical trials<span> of lipid-lowering drugs. Remnant TGRLP particles are highly atherogenic, due to their ability to enter and be retained in the arterial wall, their high cholesterol content, their ability to generate “foam cells” and an inflammatory response. Assessment of remnant cholesterol may provide information on residual risk of ACVD beyond the information provided by LDL-C, Non-HDL-C, and apoB, particularly in individuals with hypertriglyceridaemia<span>, type 2 diabetes, or metabolic syndrome<span><span>. In the Reduce-It study, icosapent ethyl was shown to have a preventive effect against CVD in very high cardiovascular risk patients with hypertriglyceridaemia treated with statins and target LDL-C. New lipid-lowering drugs will help to define efficacy and criteria in the </span>treatment of excess remnant cholesterol and hypertriglyceridaemia in the prevention of ACVD.</span></span></span></span></p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Pages 206-217"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49706054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clínica e Investigación en Arteriosclerosis has been assigned an impact factor: A goal achieved!","authors":"Josep Ribalta,&nbsp;Carlos Lahoz,&nbsp;Xavier Pintó","doi":"10.1016/j.artere.2023.07.007","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.007","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Page 201"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49705879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of atherogenic dyslipidemia, related factors and level of lipid control in the general population of Galicia. GALIPEMIAS study","authors":"Carlos Názara ,&nbsp;Rosa M. Argüeso ,&nbsp;Juan Pedro-Botet ,&nbsp;Xavier Pintó ,&nbsp;Jesús Millán ,&nbsp;Marta Pena Seijo ,&nbsp;Pablo A. Fernández ,&nbsp;M. Eugenia Ameneiros ,&nbsp;Alberto del Alamo ,&nbsp;Avelino Rodríguez ,&nbsp;José Antonio Díaz-Peromingo ,&nbsp;María Rosa Vázquez Freire ,&nbsp;Javier Muñiz ,&nbsp;Teresa R. Pérez-Castro ,&nbsp;José Luis Díaz-Díaz ,&nbsp;Antonio Pose Reino","doi":"10.1016/j.artere.2023.07.002","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.002","url":null,"abstract":"<div><h3>Objectives</h3><p>GALIPEMIAS is a study designed to establish the prevalence of familial dyslipidemia in the general population of Galicia. The objective of the present study was to assess the prevalence of atherogenic dyslipidemia (AD), its relationship with other cardiovascular risk (CVR) factors, and the degree of lipid control.</p></div><div><h3>Methods</h3><p>Cross-sectional study carried out in the general population over 18 years of age residing in Galicia and with a health card from the Galician Health Service (N = 1000). Selection of the sample by means of random sampling by conglomerates. The AD prevalence adjusted for age and sex and the related variables were analyzed.</p></div><div><h3>Results</h3><p>The prevalence of AD adjusted for age and sex was 6.6% (95% CI: 5.0%–8.3%). Arterial hypertension, altered basal glycemia, type 2 diabetes mellitus and cardiovascular disease were more frequent in subjects with AD than in the rest of the population. 47.5% of the subjects with AD had a high or very high CVR. Lipid-lowering drugs were received by 38.9% (30.5% statins) of the participants with AD (46.1% of those with high and 71.4% of those with very high CVR). 25.4% of the subjects with AD had target LDL-C levels, all of them with low or moderate CVR.</p></div><div><h3>Conclusions</h3><p>The prevalence of AD in the general adult population of Galicia is not negligible, and it was related to several CVR factors and cardiovascular disease. Despite this, this lipid alteration was underdiagnosed and undertreated.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Pages 178-184"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49760712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis","authors":"Jose A. Quesada ,&nbsp;Vicente Bertomeu-González ,&nbsp;Domingo Orozco-Beltrán ,&nbsp;Alberto Cordero ,&nbsp;Vicente F. Gil-Guillén ,&nbsp;Adriana López-Pineda ,&nbsp;Rauf Nouni-García ,&nbsp;Concepción Carratalá-Munuera","doi":"10.1016/j.artere.2023.07.006","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.006","url":null,"abstract":"<div><h3>Objective</h3><p><span>Cardiovascular risk (CVR) is conventionally calculated by measuring the total cholesterol content of high-density lipoproteins (HDL) and low-density lipoproteins (LDL). The purpose of this systematic review was to assess the CVR associated with LDL and </span>HDL particle size and number as determined by nuclear magnetic resonance (NMR) spectroscopy.</p></div><div><h3>Material and methods</h3><p>A literature search was performed using the electronic databases MEDLINE and Scopus. All cohort and case–control studies published before January 1, 2019 that met the following inclusion criteria were included: HDL-P, LDL-P, HDL-Z and/or LDL-Z measured by NMR spectroscopy; cardiovascular event as an outcome variable; risk of cardiovascular events expressed as odds ratios or hazard ratios; only adult patients. A meta-analysis was performed for each exposure variable (4 for LDL and 5 for HDL) and for each exposure measure (highest versus lowest quartile and 1-standard deviation increment).</p></div><div><h3>Results</h3><p>This review included 24 studies. Number of LDL particles was directly associated with CVR: risk increased by 28% with each standard deviation increment. LDL particle size was inversely and significantly associated with CVR: each standard deviation increment corresponded to an 8% risk reduction. CVR increased by 12% with each standard deviation increase in number of small LDL particles. HD, particle number and size were inversely associated with CVR.</p></div><div><h3>Conclusion</h3><p>Larger particle size provided greater protection, although this relationship was inconsistent between studies. Larger number of LDL particles and smaller LDL particle size are associated with increased CVR. Risk decreases with increasing number and size of HDL particles.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Pages 165-177"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49760711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The presence of activating IgG Fc receptors in macrophages aggravates the development of experimental abdominal aortic aneurysm","authors":"Laura López-Sanz ,&nbsp;Susana Bernal ,&nbsp;Luna Jiménez-Castilla ,&nbsp;Marisa Pardines ,&nbsp;Ana Hernández-García ,&nbsp;Luis Blanco-Colio ,&nbsp;José Luis Martín-Ventura ,&nbsp;Carmen Gómez Guerrero","doi":"10.1016/j.artere.2023.07.003","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.003","url":null,"abstract":"<div><h3>Introduction</h3><p><span><span>Abdominal aortic aneurysm (AAA) is a multifactorial, </span>degenerative disease<span> characterized by progressive aortic dilation and chronic activation of inflammation, proteolytic activity, and </span></span>oxidative stress<span> in the aortic wall. The immune response triggered by antibodies against antigens present in the vascular wall participates in the formation and progression of AAA through mechanisms not completely understood. This work analyses the function of specific IgG receptors (FcγR), especially those expressed by monocytes/macrophages, in the development of experimental AAA.</span></p></div><div><h3>Methods</h3><p><span>In the elastase-induced AAA model, the abdominal aortas<span> from wildtype and FcγR deficient mice with/without macrophage adoptive transfer were analysed by histology and quantitative PCR. In vitro, RAW 264.7 macrophages were transfected with RNA interference of FcγRIV/CD16.2 or treated with </span></span>Syk kinase inhibitor<span> before stimulation with IgG immune complexes.</span></p></div><div><h3>Results</h3><p><span>Macrophage adoptive transfer in FcγR deficient mice increased the susceptibility to AAA development. Mice receiving macrophages with functional FcγR exhibited higher aortic diameter increase, higher content of macrophages and B lymphocytes<span>, and upregulated expression of chemokine CCL2, cytokines (TNFα and IL-17), </span></span>metalloproteinase<span><span><span> MMP2, prooxidant enzyme NADPH oxidase-2, and the isoforms FcγRIII/CD16 and FcγRIV/CD16.2. In vitro, both FcγRIV/CD16.2 </span>gene silencing and Syk inhibition reduced cytokines and </span>reactive oxygen species production induced by IC in macrophages.</span></p></div><div><h3>Conclusions</h3><p>Activation of macrophage FcγR contributes to AAA development by inducing mediators of inflammation, proteolysis, and oxidative stress. Modulation of FcγR or effector molecules may represent a potential target for AAA treatment.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Pages 185-194"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49760713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk factors and death in South America","authors":"Patricio López-Jaramillo ,&nbsp;José P. López-López","doi":"10.1016/j.artere.2023.07.001","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.001","url":null,"abstract":"<div><p>We present cardiovascular disease (CVD) incidence and mortality rates reported for South America stratified by country, sex, and urban/rural location in a multinational cohort included in the Population Urban Rural Epidemiological Study (PURE). This study included 24718 participants from 51 urban and 49 rural communities in Argentina, Brazil, Chile, and Colombia and the mean follow-up was 10.3 years. CVD incidence and mortality rates were calculated for the total cohort and in subpopulations. Hazard ratios and population attributable fractions (PAFs) for CVD and death were examined for 12 modifiable risk factors, grouped as metabolic (hypertension, diabetes, abdominal obesity, and high non-HDL cholesterol), behavioural (smoking, alcohol, diet quality, and physical activity) and other (education, household air pollution, strength, and depression). The leading causes of death were CVD (31.1%), cancer (30.6%), and respiratory diseases (8.6%). Approximately 72% of the PAFs for CVD and 69% of the PAFs for deaths were attributed to 12 modifiable risk factors. For CVD, the main PAFs were due to hypertension (18.7%), abdominal obesity (15.4%), smoking (13.5%), low muscle strength (5.6%), and diabetes (5.3%). For death, the main PAFs were smoking (14.4%), hypertension (12.0%), low educational level (10.5%), abdominal obesity (9.7%), and diabetes (5.5%). Cardiovascular diseases, cancer, and respiratory diseases account for more than two-thirds of deaths in South America. Men have consistently higher CVD rates and mortality than women. A large proportion of CVD and premature deaths could be avoided by controlling metabolic risk factors and smoking, which are the main risk factors in the region for both CVD and all-cause mortality.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Pages 195-200"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49760715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?","authors":"Juan Carlos Laguna Egea,&nbsp;Núria Roglans Ribas,&nbsp;Roger Bentanachs Raset","doi":"10.1016/j.artere.2023.07.004","DOIUrl":"https://doi.org/10.1016/j.artere.2023.07.004","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 4","pages":"Pages 202-205"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49760722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary modulation of advanced glycation end products metabolism on carotid intima-media thickness in type 2 diabetes patients: From the CORDIOPREV study","authors":"Elena M. Yubero-Serrano ,&nbsp;Francisco M. Gutiérrez-Mariscal ,&nbsp;Purificación Gómez-Luna ,&nbsp;Juan F. Alcalá-Diaz ,&nbsp;Pablo Pérez-Martinez ,&nbsp;José López-Miranda","doi":"10.1016/j.artere.2023.05.006","DOIUrl":"https://doi.org/10.1016/j.artere.2023.05.006","url":null,"abstract":"<div><h3>Background</h3><p>Advanced glycation end products (AGEs) are pro-oxidant and cytotoxic compounds involved in the progression of chronic diseases as cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The total body burden of AGEs also depend of those consume through the diet. Our aim was to analyze whether the reduction of AGE levels, after the consumption of two-healthy diets were associated with a greater decrease of intima-media thickness of both common carotid arteries (IMT-CC) in patients with T2DM and coronary heart disease (CHD).</p></div><div><h3>Methods</h3><p>540 CHD patients with T2DM, at baseline, from the CORDIOPREV study, were divided into two groups: (1) Responders, patients whose IMT-CC was reduced or not changed after dietary intervention and (2) Non-responders, patients whose IMT-CC was increased after dietary intervention. A total of 423 completed baseline and the 5-year follow-up carotid ultrasounds were analyzed in this study.</p></div><div><h3>Results</h3><p>Our data showed that Responders, despite had a higher baseline IMT-CC and serum methylglyoxal (MG) levels than Non-responders, showed a reduction of serum levels of this glycotoxin after dietary intervention. Conversely, in patients whose IMT-CC was increased after dietary intervention (Non-responders), serum MG levels were increased. Moreover, an increase of circulating level of AGEs (and in particular, MG), after dietary intervention, could be considered a risk factor for the progression of atherosclerosis in patients with T2DM and CHD.</p></div><div><h3>Conclusion</h3><p>These results support the importance of identifying underlying mechanisms in the context of secondary prevention of CVD that would provide therapeutic targets to reduce the high risk of cardiovascular events of these patients.</p><p>Clinical Trial registration-URL: <span>https://clinicaltrials.gov/ct2/show/NCT00924937</span><svg><path></path></svg>.</p><p>Unique Identifier: <span>NCT00924937</span><svg><path></path></svg>.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 3","pages":"Pages 105-114"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49711304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing muscular strength to improve cardiometabolic risk factors","authors":"Patricio Lopez-Jaramillo ,&nbsp;Jose P. Lopez-Lopez ,&nbsp;Maria Camila Tole ,&nbsp;Daniel D. Cohen","doi":"10.1016/j.artere.2023.06.001","DOIUrl":"https://doi.org/10.1016/j.artere.2023.06.001","url":null,"abstract":"<div><p>Cardiovascular diseases (CVDs) remain the leading cause of worldwide death, accounting for significant morbidity, mortality, disability, and reduced quality of life. The global prevalence of cardiovascular (CV) risk factors, such as type 2 diabetes mellitus, hypertension, dyslipidemia, and obesity, has grown exponentially in the last decades, particularly in low-medium income countries, and it's projected to increase rapidly in the coming years as the population progressively ages, leading to increased cardiovascular disease (CVD) and associated mortality. In fact, data from the global burden of disease study shows that CV mortality, associated disability-adjusted life years (DALYs), and years of life lost (YLL) have increased steadily, nearly doubling from 1990 to 2019.</p><p>Recent evidence proves the existence of an inverse association between hand grip strength (HGS), as a proxy for global muscle strength, with all-cause mortality, CV mortality, and the development of several chronic diseases. These associations have been demonstrated recurringly across the entire lifespan, beginning in childhood, and carrying on throughout adult life. Mounting evidence strongly indicates that HGS is an early predictor of chronic disease in premorbid populations and a therapeutic target for CVD prevention. Recent clinical trials have consistently shown that resistance exercise, which increases strength and potentially muscle mass, significantly improves the control of known CVD risk factors, reduces the risk of all-cause death and cardiovascular mortality.</p><p>In this review, we explore the latest evidence regarding the association between low muscle strength and diverse metabolic alterations, along with the interventions that could improve cardiometabolic risk factors, while simultaneously increasing muscle fitness.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 3","pages":"Pages 144-154"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49706052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}